HIV envelope glycoprotein immunogens
The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus, the Env polypeptide comprising at least the amino acid residues K275, D276 and R278, wherein said numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
1. An isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus, wherein said Env polypeptide comprises at least the amino acid residues K275, D276 and R278, wherein the numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
2. The isolated, recombinant or synthetic polypeptide according to claim 1 , not comprising at least 4, 5, 6 or 7 amino acids of the consecutive amino acid stretch RSNNSNK of the amino acid sequence of SEQ ID NO: 2, wherein the numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
3. The isolated, recombinant or synthetic polypeptide according to claim 1 , comprising at least one amino acid residue selected from the group consisting of: A199, D386, D462, and S471, wherein the numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
4. The isolated, recombinant or synthetic polypeptide according to claim 1 , comprising at least 1, more preferably 2, 3, 4, 5, 6, 7, 8 or 9 amino acid residue(s) selected from the group consisting of: R169, H173, A174, K178, I181, P183, N188, T189, and S190, wherein the numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
5. The isolated, recombinant or synthetic polypeptide according to claim 1 , wherein said Env protein has an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 2.
6. The isolated, recombinant or synthetic polypeptide according to claim 1 , comprising at least one amino acid residue selected from the group consisting of W316 and K64, wherein the numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
7. The isolated, recombinant or synthetic polypeptide according to claim 1 , wherein said Env polypeptide is of HIV-1.
8. A trimer comprising the isolated, recombinant or synthetic polypeptide according to claim 1 .
9. A virus like particle (VPL), nanoparticle or pseudoparticle comprising the isolated, recombinant or synthetic polypeptide according to claim 1 or the trimer according to claim 8 .
10. A pharmaceutical composition comprising the isolated, recombinant or synthetic polypeptide according to claim 1 , or the trimer according to claim 8 , or the virus like particle, nanoparticle or pseudoparticle according to claim 9 , and a pharmaceutically acceptable carrier, excipient, or diluent, and optionally, an adjuvant.
11. The isolated, recombinant or synthetic polypeptide according to claim 1 , or the trimer according to claim 8 , or the virus like particle, nanoparticle or pseudoparticle according to claim 9 , or the pharmaceutical composition according to claim 10 for use in a medical treatment.
12. The isolated, recombinant or synthetic polypeptide according to claim 1 , or the trimer according to claim 8 , or the virus like particle, nanoparticle or pseudoparticle according to claim 9 , or the pharmaceutical composition according to claim 10 for use in the treatment of an HIV infection or for use in the prevention of an HIV infection.
13. A nucleic acid encoding the isolated, recombinant or synthetic polypeptide according to claim 1 .
14. A vector comprising the nucleic acid according to claim 13 .
15. An isolated or recombinant eukaryotic or prokaryotic host cell comprising the vector of claim 14 .